Related Experiment Video
Updated: Jun 12, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
[Pulmonary arterial hypertension: past, present and future]
1Department of Pathobiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. aytekim@ccf.org
Abstract:
Pulmonary arterial hypertension (PAH) is a rare disease with incidence of approximately two to five per million per year and it is characterized by high pulmonary artery pressure. The mechanism of high blood pressure in pulmonary arteries is still unknown and also the pathogenesis of idiopathic PAH is not fully understood. Despite recent advances in therapy, PAH remains a progressive disease with high mortality and morbidity. Traditional hemodynamic markers of disease severity and progression have significant limitations and non-invasive markers are needed to guide follow-up and the effectiveness of therapy in idiopathic PAH patients. Our goal in this review is to give an overview of pulmonary hypertension and to provide researchers with a better understanding of this disease.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

